Charlotte blood cancer advocate David Wallace shares lessons from six years with undetectable disease ahead of Blood Cancer Awareness Month.
CHARLOTTE, NC, UNITED STATES, August 11, 2026 /EINPresswire.com/ — PV Reporter has released a patient-focused educational resource detailing how founder David Wallace reached complete molecular remission from polycythemia vera (PV), a rare blood cancer. Debuting ahead of September’s Blood Cancer Awareness Month, the guide equips patients with information to talk with their doctors about driver mutations, treatment objectives, and care from MPN specialists.
The guide is accessible at https://pvreporter.com/polycythemia-vera-molecular-remission/.
Wallace received his PV diagnosis in 2009. His blood counts are now normal, and the JAK2 mutation responsible for his condition has stayed undetectable for over six years. His JAK2 V617F allele burden dropped from roughly 28 percent to undetectable—a result termed complete molecular remission. Remission does not equate to a cure, and treatment results differ widely among individuals.
This newly released resource outlines Wallace’s journey from phlebotomy through pegylated interferon and eventually to combination therapy with ruxolitinib. It also describes how research he encountered while attending the 2015 American Society of Hematology annual meeting prompted him to raise the combination approach with his doctor. During treatment, Wallace developed skin cancer requiring ongoing surveillance, experienced infections, and underwent numerous dose adjustments. He continues on a low-dose maintenance regimen.
In the early years of his PV journey, Wallace consulted five different hematologists while searching extensively for a physician with strong MPN expertise and a willingness to engage with current studies. His switches in doctors reflected a broader quest for informed care and were not directly tied to combination therapy. After asking the chief of hematology at his cancer center for “a doctor who knows more about PV than I do,” he was directed to the specialist who still treats him today.
“Most PV patients are never told that deep remission is even on the table,” Wallace said. “Newly diagnosed patients must learn about their illness, understand what each treatment is intended to accomplish and make sure they are seeing a true MPN specialist.”
Published studies indicate that deep molecular responses can be achieved with pegylated interferon alone as well as in combination with ruxolitinib, though results vary and complete molecular remission remains uncommon. The guide also points patients to PV Reporter’s free, doctor-vetted MPN Specialist Locator at https://pvreporter.com/mpn-specialists-cancer-treatment-centers/.
About PV Reporter
PV Reporter was established by David Wallace in 2013 to deliver patient-friendly information on myeloproliferative neoplasms. The site publishes emerging MPN research and maintains a doctor-vetted specialist locator along with a free clinical trial finder. Through PV Reporter and the nonprofit MPN Cancer Connection, Wallace has supported thousands of patients and caregivers worldwide.
David Wallace
PV Reporter
+1 704-323-6771
david@pvreporter.com
